Literature DB >> 23474147

Diagnostic challenges of amyloidosis in Waldenström macroglobulinemia.

Giovanni Palladini1, Giampaolo Merlini.   

Abstract

Amyloidosis associated with immunoglobulin M clones is a distinct clinical entity that poses specific challenges to clinicians. Although there is substantial overlap, the pattern of organ involvement is peculiar, with higher frequencies of lung, lymph nodes, and peripheral nervous system involvement. Early diagnosis is vital to start effective therapy before irreversible organ damage has occurred and should be based on markers of initial, asymptomatic organ dysfunction, such as natriuretic peptides for heart involvement and albuminuria for renal amyloidosis. Immunoglobulin M clones can give rise to both light chain (AL) and reactive (AA) amyloidosis, and once the diagnosis of amyloidosis is made, correct amyloid typing is necessary to design appropriate therapy and follow-up. Prognostic stratification should include serum albumin concentration, which is an independent prognostic factor.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23474147     DOI: 10.1016/j.clml.2013.02.001

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  3 in total

1.  True, true unrelated? Coexistence of Waldenström macroglobulinemia and cardiac transthyretin amyloidosis.

Authors:  Avinainder Singh; Hallie I Geller; Kevin M Alexander; Robert F Padera; Richard N Mitchell; Sharmila Dorbala; Jorge J Castillo; Rodney H Falk
Journal:  Haematologica       Date:  2018-04-19       Impact factor: 9.941

2.  Autopsy findings in a patient with primary systemic AL (kappa light chain) amyloidosis.

Authors:  Felipe Lourenço Ledesma; Jussara Bianchi Castelli
Journal:  Autops Case Rep       Date:  2021-05-06

Review 3.  How I treat elderly patients with plasma cell dyscrasias.

Authors:  Maria Gavriatopoulou; Despoina Fotiou; Ioannis Ntanasis-Stathopoulos; Efstathios Kastritis; Evangelos Terpos; Meletios Athanasios Dimopoulos
Journal:  Aging (Albany NY)       Date:  2018-12-18       Impact factor: 5.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.